Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Articles of Association for Genmab A/S12 Mar 2015
Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 201511 Mar 2015
Report Pursuant to Section 28a of the Danish Securities Trading Act11 Mar 2015
Genmab A/S Summons Annual General Meeting3 Mar 2015
Genmab Announces That Agreement to Transfer Ofatumumab Collaboration to Novartis is Now Effective2 Mar 2015
Genmab 2014 Annual Report2 Mar 2015
Genmab Enters Commercial DuoBody Technology Agreement with BioNovion in the Field of Immuno-Oncology19 Feb 2015
Fourth Quarter and Full Year 2014 Net Sales Figures for Arzerra (ofatumumab)
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
4 Feb 2015
Major Shareholder Announcement4 Feb 2015
Genmab Announces Preliminary Results in Phase II Study of Daratumumab in Double Refractory Multiple Myeloma3 Feb 2015
Genmab to Present at the 33rd Annual J.P. Morgan Healthcare Conference8 Jan 2015
Articles of Association for Genmab A/S18 Dec 2014
  • Previous
  • 1
  • More pages
  • 76
  • 77
  • 78
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863